GlassScriptPhysician profile
Elizabeth Schultz
NPI 1467192450
$7,924.12
in general payments reported to CMS, 2019-2025
22 companies · $2,689 in 2025
The $2,689 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $545 · 2023: $1,605 · 2024: $3,084 · 2025: $2,689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,158 · Education: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,157.81 |
| Education | $220.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,313.69 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $894.69 | 2022-2025 | Caplyta |
| Abbvie INC. | $735.66 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $640.28 | 2022-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $528.91 | 2024-2025 | Fanapt |
| Alkermes, INC. | $502.70 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $457.76 | 2024-2025 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $411.65 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $404.87 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $396.67 | 2022-2025 | Trintellix |
| Lundbeck LLC | $377.53 | 2022-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $318.00 | 2022-2025 | Ingrezza |
| Corium, LLC | $295.44 | 2022-2024 | Azstarys, Azstarys |
| Almatica Pharma LLC | $290.19 | 2022-2025 | Loreev Xr |
| Neos Therapeutics, LP | $101.57 | 2022-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $66.61 | 2022-2023 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $64.12 | 2022 | |
| Idorsia Pharmaceuticals US INC | $37.02 | 2023-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $23.94 | 2024 | |
| Recordati_rare_diseases_inc. | $23.61 | 2024 | Isturisa, Signifor Lar |
| Owp Pharmaceuticals, INC. | $21.95 | 2024 | Subvenite |
| E.R. Squibb & Sons, L.L.C. | $17.26 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.